Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial (Q33785136)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

Krzysztof Strojek

1

object named as

Krzysztof Strojek

1 reference

Europe PubMed Central

29 July 2017

author name string

Kun-Ho Yoon

2

1 reference

Europe PubMed Central

29 July 2017

Veronika Hruba

3

1 reference

Europe PubMed Central

29 July 2017

Jennifer Sugg

4

1 reference

Europe PubMed Central

29 July 2017

Anna Maria Langkilde

5

1 reference

Europe PubMed Central

29 July 2017

Shamik Parikh

6

1 reference

Europe PubMed Central

29 July 2017

publication date

12 June 2014

1 reference

Europe PubMed Central

29 July 2017

Diabetes Therapy

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

267-283

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

copyright license

Creative Commons Attribution 4.0 International

1 June 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s13300-014-0072-0

0 references

Fasting serum C-peptide levels predict cardiovascular and overall death in nondiabetic adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Diabetes medications and body weight

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Improving efficiency of inferences in randomized clinical trials using auxiliary covariates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Diabetes, hypertension, and cardiovascular disease: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Infections in patients with diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Treatment of vulvovaginal candidiasis in patients with diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065289

4 July 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Implications of new hypertension guidelines in the United States.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Urinary tract infections in patients with diabetes treated with dapagliflozin.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0072-0

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24920277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic investigation on the interaction of bovine serum albumin with ZnO nanoparticles using fluorescence spectroscopy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24920277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantifying the risk of infectious diseases for people with diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24920277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13300-014-0072-0

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33785136&oldid=1861476547"